Avidity Partners 13F holdings, Q2 2024
Holdings as of June 30, 2024 · filings on SEC EDGAR · latest filing →
Avidity Partners disclosed 85 US equity positions worth $2.4bn in its Q2 2024 13F filing. The largest position was ISRG at 4.6% of the reported book, followed by BSX and NTRA. Against the Q1 2024 filing, it opened 6 new positions, added to 22 and reduced 17 among the top 50 holdings.
What did Avidity Partners own in Q2 2024? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ISRG INTUITIVE SURGICAL INC | Healthcare | 4.6% | $109.0m | 245,000 | 8% | added |
| 2 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 3.8% | $90.1m | 1,170,100 | -40% | reduced |
| 3 | NTRA NATERA INC | Healthcare | 3.5% | $83.0m | 766,500 | -5% | reduced |
| 4 | ARVN ARVINAS INC | Healthcare | 3.4% | $79.5m | 2,987,845 | 0% | held |
| 5 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 3.2% | $75.6m | 1,120,000 | 11% | added |
| 6 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 3.2% | $75.5m | 2,917,231 | 7% | added |
| 7 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.9% | $68.5m | 3,335,000 | 38% | added |
| 8 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 2.9% | $67.6m | 491,000 | -8% | reduced |
| 9 | AVTR AVANTOR INC | Healthcare | 2.8% | $65.4m | 3,086,000 | 15% | added |
| 10 | CI THE CIGNA GROUP | Healthcare | 2.6% | $61.0m | 184,500 | 0% | held |
| 11 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 2.5% | $58.1m | 544,500 | -7% | reduced |
| 12 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.3% | $53.9m | 222,000 | -9% | reduced |
| 13 | REGN REGENERON PHARMACEUTICALS | Healthcare | 2.1% | $50.4m | 48,000 | -29% | reduced |
| 14 | ILMN ILLUMINA INC | Healthcare | 2.1% | $49.9m | 478,000 | 3% | added |
| 15 | THC TENET HEALTHCARE CORP | Healthcare | 2.1% | $49.5m | 372,000 | -38% | reduced |
| 16 | ABBV ABBVIE INC | Healthcare | 2.0% | $47.6m | 277,800 | 22% | added |
| 17 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 1.9% | $44.2m | 80,000 | 119% | added |
| 18 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 1.8% | $42.2m | 1,075,000 | 24% | added |
| 19 | 2655787D BLUEPRINT MEDICINES CORP | 1.8% | $41.3m | 383,000 | -10% | reduced | |
| 20 | CGON CG ONCOLOGY INC | Healthcare | 1.7% | $40.9m | 1,296,225 | -11% | reduced |
| 21 | MRK MERCK & CO INC | Healthcare | 1.7% | $40.2m | 325,000 | -35% | reduced |
| 22 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 1.7% | $39.5m | 960,000 | 3% | added |
| 23 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 1.7% | $39.2m | 1,117,000 | 40% | added |
| 24 | DHR DANAHER CORPORATION | Healthcare | 1.6% | $37.5m | 150,000 | 4% | added |
| 25 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.5% | $35.2m | 840,219 | 119% | added |
| 26 | UTHR UNITED THERAPEUTICS CORP DEL | Healthcare | 1.5% | $35.0m | 110,000 | -49% | reduced |
| 27 | INCY INCYTE CORP | Healthcare | 1.4% | $32.1m | 529,000 | – | new |
| 28 | SGRY SURGERY PARTNERS INC | Healthcare | 1.3% | $31.1m | 1,306,477 | -10% | reduced |
| 29 | CATX PERSPECTIVE THERAPEUTICS INC | 1.3% | $30.3m | 3,037,668 | – | new | |
| 30 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 1.3% | $30.3m | 376,000 | -13% | reduced |
| 31 | XENE XENON PHARMACEUTICALS INC | Healthcare | 1.2% | $29.4m | 754,000 | 6% | added |
| 32 | DXCM DEXCOM INC | Healthcare | 1.2% | $29.4m | 259,000 | 46% | added |
| 33 | RVMD REVOLUTION MEDICINES INC | Healthcare | 1.2% | $29.3m | 755,000 | 19% | added |
| 34 | INSM INSMED INC | Healthcare | 1.2% | $28.8m | 430,000 | – | new |
| 35 | INTRA-CELLULAR THERAPIES INC | 1.2% | $27.4m | 400,000 | -33% | reduced | |
| 36 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.2% | $27.2m | 1,559,826 | – | new |
| 37 | GKOS GLAUKOS CORP | Healthcare | 1.1% | $26.5m | 224,000 | 0% | held |
| 38 | NGNE NEUROGENE INC | 1.1% | $26.5m | 727,537 | 56% | added | |
| 39 | ARGX ARGENX SE | Healthcare | 1.1% | $26.0m | 60,500 | – | new |
| 40 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 1.1% | $25.0m | 731,104 | -36% | reduced |
| 41 | ESTA ESTABLISHMENT LABS HLDGS INC | Healthcare | 1.0% | $24.1m | 531,000 | 136% | added |
| 42 | IMVT IMMUNOVANT INC | Healthcare | 1.0% | $24.0m | 908,000 | 80% | added |
| 43 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.0% | $23.7m | 1,100,000 | 7% | added |
| 44 | LNTH LANTHEUS HLDGS INC | Healthcare | 1.0% | $23.3m | 290,000 | -40% | reduced |
| 45 | PCVX VAXCYTE INC | Healthcare | 0.9% | $21.4m | 284,000 | 0% | held |
| 46 | APGE APOGEE THERAPEUTICS INC | Healthcare | 0.8% | $19.2m | 487,000 | 27% | added |
| 47 | JASPER THERAPEUTICS INC | 0.8% | $17.8m | 782,000 | 3% | added | |
| 48 | NMRA NEUMORA THERAPEUTICS INC. | Healthcare | 0.8% | $17.7m | 1,800,000 | 0% | held |
| 49 | LEGN LEGEND BIOTECH CORP | Healthcare | 0.7% | $17.6m | 398,000 | -40% | reduced |
| 50 | GILD GILEAD SCIENCES INC | Healthcare | 0.7% | $17.5m | 255,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.